LIFE SCIENCE PRODUCTS MARKET ANALYSIS

Life Science Products Market, By Product (Recombinant Proteins (Immune Checkpoint Regulators, Chemokines, Growth Factors, Cytokines, Colony Stimulating Factors, Hormones, Enzymes & Inhibitors, Others), Cell Lines (Immunotherapy Cell Lines, Ion Channel Cell Lines, GPCR Cell Lines, Cell Signaling Pathway Cell Lines, Gene Knockout Cell Lines, Cancer Cell Lines, Others), Antibodies (Immune Checkpoint Antibodies, Epitope Tag Antibodies, Isotype Control Antibodies (Research Use, In-vivo Grade), Primary Antibodies (Research Use, In-vivo Grade), Assay Antibodies (includes secondary antibodies), Others(Viable Tumor Samples, Tumor Tissue Microarrays)), By Application (Drug Discovery & Development, Basic Research, Toxicity Screening, Biopharmaceutical Production, Drug Screening, Tissue Engineering, Forensic Testing), By End User (Biopharmaceutical Companies, Contract Research Organizations (CROs), Academic & Research Institutes, Forensic Science Laboratories, Food & Beverage Companies, Diagnostic Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jun 2023
Code : CMI3652
Pages :180
Formats :
Excel and PDF
Industry : Biotechnology

Regional Analysis

Global Life Science Products Market- Regional Analysis

Among all regions, North America is expected to dominate the global market over the forecast period. This is attributed to an increase in product approval by the regulatory bodies in this region. For instance, in March 2022, Bristol Myers Squibb, a pharmaceutical company, announced that Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Asia Pacific region is expected to be the second dominating region over the forecast period, due to an increase in the facility expansion in the region. For instance, in July 2020, Laurus Bio Pvt Ltd., a biotechnology company, announced plans to expand its manufacturing capability by building a second recombinant protein manufacturing facility in India.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa